5α-Reductase Inhibitors Increase Acute Coronary Syndrome Risk in Patients with Benign Prostate Hyperplasia

    March 2015 in “ Journal of Endocrinological Investigation ”
    Chi-Hung Chou, Cheng-Li Lin, Ming-Chia Lin … Chia-Hung Kao
    Studysummary This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 9

    1. Changes of Metabolic Profile in Men Treated for Androgenetic Alopecia with 1 mg Finasteride Endocrine Regulations · 2010
    2. The Effect of 5α-Reductase Inhibition With Dutasteride and Finasteride on Bone Mineral Density, Serum Lipoproteins, Hemoglobin, Prostate Specific Antigen, and Sexual Function in Healthy Young Men ˜The œJournal of urology/˜The œjournal of urology · 2008
    3. Changes in Hair Weight in Men with Androgenetic Alopecia After Treatment with Finasteride (1 mg Daily): Three- and Four-Year Results Journal of The American Academy of Dermatology · 2006
    4. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor ˜The œJournal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism · 2004
    5. Comparison of Clinical Trials with Finasteride and Dutasteride PubMed · 2004
    6. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia The New England Journal of Medicine · 2003
    7. The Long-Term Effect of Specific Type II 5alpha-Reductase Inhibition with Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial PubMed · 2002
    8. The Long-Term Effect of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo-Controlled Trial The Journal of Urology · 2002
    9. Effect of Finasteride, a 5 Alpha-Reductase Inhibitor, on Serum Gonadotropins in Normal Men The Journal of Clinical Endocrinology and Metabolism · 1992